A Comprehensive Analysis of Hengrui
Authors
Yifan Gao1, *, †, Yuke Wang2, †, Yixiang Zhang3, †
1International Business School Suzhou at XJTLU, Xi’an Jiaotong-liverpool University, SuZhou, Jiangsu, 215028 China
2School of Social Science, University of California, Irvine, 92617 United States
3The Paul Merage School of Business, University of California, Irvine, 92617 United States
†
Theses authors contributed equally
*Corresponding author Email: Yifan.Gao18@student.xjtlu.edu.cn
Corresponding Author
Yifan Gao
Available Online 1 July 2022.
- DOI
- 10.2991/aebmr.k.220603.186How to use a DOI?
- Keywords
- Pharmaceutical Industry; Hengrui Pharmaceutical; Financial Analysis
- Abstract
China has one of the largest pharmaceutical markets in the world. However, few studies have focused on domestic Chinese pharmaceutical companies. This paper evaluates the corporate operations of Hengrui by analyzing them at various levels. Hengrui has been in a good financial position and growing steadily for the past few years. However, Hengrui needs to improve its research capabilities to ensure its long-term competitiveness in the Chinese and international pharmaceutical markets.
- Copyright
- © 2022 The Authors. Published by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license.
Cite this article
TY - CONF AU - Yifan Gao AU - Yuke Wang AU - Yixiang Zhang PY - 2022 DA - 2022/07/01 TI - A Comprehensive Analysis of Hengrui BT - Proceedings of the 2022 2nd International Conference on Enterprise Management and Economic Development (ICEMED 2022) PB - Atlantis Press SP - 1151 EP - 1158 SN - 2352-5428 UR - https://doi.org/10.2991/aebmr.k.220603.186 DO - 10.2991/aebmr.k.220603.186 ID - Gao2022 ER -